UPDATE: The @MHRAgovuk issued a temporary authorization for emergency use of our #COVID19 vaccine with @BioNTech_Group in the United Kingdom.

This marks the first authorization of a vaccine to help fight the pandemic following a worldwide trial.

You’ve got questions, we’ve got answers. Angela Hwang, our Group President, Biopharmaceuticals, answers questions on our #COVID19 vaccine candidate.

Kicking off the ?, Q: What is the status of the Pfizer and BioNTech investigational COVID-19 vaccine candidate? (1/7)

A: pic.twitter.com/ZkibhPEav7